Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

New Therapeutic Target Found For Aggressive Pediatric Cancers With Few Treatment Options

(MD Anderson News) Feb 11, 2019 - Preclinical study identifies vulnerability in orphan cancers with SMARCB1 mutations, spurs launch of Phase II clinical trial.

Hospital Mergers Improve Health? Evidence Shows the Opposite

(New York Times) Feb 11, 2019 - The claim was that larger organizations would be able to harness economies of scale and offer better care.

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

(Astellas) Feb 11, 2019 - Pfizer Inc. and Astellas Pharma Inc. announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Interaction Between Immune Factors Can Trigger Cancer

(The Harvard Gazette) Feb 11, 2019 - Massachusetts General Hospital (MGH) research team has identified interaction between two elements of the immune system as critical for the transformation of a protective immune response into chronic, cancer-promoting inflammation.

FDA Panel to Assess Risks of Women’s Surgical Mesh

(Wall Street Journal) Feb 12, 2019 - A mesh device used in women’s pelvic surgery that has led to thousands of lawsuits is being evaluated by a Food and Drug Administration panel Tuesday.

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

(MarketWatch) Feb 11, 2019 - Bristol-Myers Squibb Company today announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

What to Watch at This Week’s Cancer Summit: Nektar, Merck, Pfizer Data

(Bloomberg) Feb 11, 2019 - Investors are preparing for the release of key clinical-development data at the American Society of Clinical Oncology’s three-day Genitourinary Cancers Symposium, or ASCO GU, kicking off on Thursday in San Francisco.

Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU

(MarketWatch) Feb 11, 2019 - First-time data from pivotal phase 3 KEYNOTE-426 trial showing KEYTRUDA® (pembrolizumab) in combination with Inlyta® (axitinib) significantly improved OS, PFS and ORR compared to sunitinib monotherapy in first-line treatment of advanced renal cell carcinoma. Three new KEYTRUDA combination datasets from the largest study of anti-PD-1 therapy in metastatic prostate cancer (KEYNOTE-365).

Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review

(Yahoo! Finance) Feb 12, 2019 - Pfizer and its partner Merck KGaA announced that the supplemental Biologics License Application (sBLA) for Bavencio (avelumab), in combination with Pfizer’s another cancer drug Inlyta (axitinib) was granted priority review by the FDA.

Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium

(MarketWatch) Feb 11, 2019 - Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data with longer follow-up on sacituzumab govitecan, its lead investigational ADC, in patients with metastatic urothelial cancer (mUC) who have relapsed or are refractory to chemotherapies and immune checkpoint inhibitors (CPIs), have been accepted for an oral presentation at this year's Genitourinary Cancers Symposium (ASCO-GU).